1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 33,00 € Taxes included to order
    Pages Iconography Videos Other
    2 1 0 0

Joint Bone Spine
Volume 83, n° 2
pages 243-244 (mars 2016)
Doi : 10.1016/j.jbspin.2015.08.002
accepted : 3 Mars 2015
Posterior reversible encephalopathy syndrome (PRES) in a patient taking adalimumab for spondyloarthritis

Thibault Mahévas a, Olivier Lidove a, Salim Ahmed Yahia b, Salhi Hayet c, Bernadette Xerri-Campano a, Jean-Marc Ziza a,
a Service de rhumatologie-médecine interne, groupe hospitalier Diaconesses-Croix-Saint-Simon, 125, rue d’Avron, 75020 Paris, France 
b Service de rhumatologie, hôpital Henri-Mondor, 94000 Créteil, France 
c Service de neurologie, hôpital Henri-Mondor, 94000 Créteil, France 

Corresponding author.

Keywords : Adalimumab, Posterior reversible encephalopathy syndrome, Spondyloarthropathy, TNFα antagonist, Pharmacovigilance

© 2015  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline